Matthias Will

Matthias Will is a seasoned leader in the biotechnology and pharmaceutical industries, currently serving as Chief Development Officer at Autolus Therapeutics, where Matthias leads a team focused on advancing cell therapies for patients with life-threatening diseases. Prior experience includes roles as Chief Medical Officer at Dren Bio, Inc., overseeing the development of innovative therapies for T-cell lymphomas and autoimmune diseases, and as VP of Clinical Development at both CRISPR Therapeutics and CytomX Therapeutics, where Matthias was instrumental in the clinical advancement of groundbreaking treatments. With a strong background in oncology, including medical director positions at Gilead Sciences and Novartis, Matthias has a proven track record in late-stage development, market access strategies, and the launch of targeted therapies. Educational qualifications include multiple medical degrees from prestigious institutions, including Harvard Medical School and the University of Tübingen, complemented by a residency in Hematology & Oncology.